Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Devicare S.L.. (5/3/19). "Press Release: Devicare Launches Lit-Control in the US with Diem Labs".

Region Region United States (USA)
Organisations Organisation Devicare S.L.
  Organisation 2 Diem Labs LLC
Products Product Lit-Control® pH Meter
  Product 2 crowdfunding
Index terms Index term Diem Labs–Devicare: medical device, 201905– collab marketing of Lit-Control in the US by Diem Labs LLC
  Index term 2 Devicare–SEVERAL: investment, 201905– crowdfunding compaign via Capital Cell platform
Person Person Garganta, Rosendo (Devicare S.L. 201504 Founder + CEO)

Devicare is taking the leap into the US healthcare market with its new partner Diem Labs, LLC to introduce an innovative digital medical solution (DTx) in the urology field in the country.

The official launch of Lit-Control® take place in the American Urological Association Annual Meeting (BOOTH 3440), held from 3 to 6 May in Chicago, which features the company’s CEO, Rosendo Garganta. AUA 2019 brings together more than 16,000 urologists from across the world.

“As a result of our research and technology, selling our star product for non-surgical treatment of renal lithiasis or kidney stones in the US is an extraordinary target milestone for any company in the sector. We are fulfilling Devicare’s worldwide vision with business agreements in more than 25 countries with different pharmaceutical companies in just two years” explains Rosendo Garganta.

Potential in the US

Renal lithiasis is the third most common frequent urological disease, affecting 12% of the US population.

Devicare has developed Lit-Control® to be a comprehensive medical solution: a medical device that measures the patient’s pH, three medical foods to alkalise, acidify and protect the kidney, and a future app for doctors and patients that allows the medication dose to be adjusted and help doctors and patients to manage the disease. All the products are patented, with 6 clinical studies and 9 scientific publications.

The company currently features a staff of 25 people, a management team with extensive experience in the biomedical and pharmaceutical sector, and a scientific and clinical advisory board that includes leading international urologists.

Invest in Devicare

In order to continue accelerating the company’s growth, on 6 May Devicare will start up a crowdfunding campaign on the specialised Capital Cell platform (Spain / UK). If you are interested in investing, contact us here.

De Coninck, V., Keller, EX., Rodríguez-Monsalve, M., Haymann, JP., Doizi, S., Traxer, O. (2018). Evaluation of a portable urinary pH meter and reagent strips. Journal Endourology. doi: 10.1089/end.2018.0202

Record changed: 2023-06-05


Picture Berlin Partner Top News Tacalyx Extends Seed Round to €14m 650x200px

More documents for Devicare S.L.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top